Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GSK1358820 (Botox) in Japanese OAB Patients
NCT02820844Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2016
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing GSK1358820 100 U with Placebo (2 arms). Primary endpoint: Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 12. Started Aug 2016; status: completed.
02
Drugs
Onabotulinumtoxina + hydrogel
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02820844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820844.